Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyapatite vs Fluoride Toothpaste for MIH Remineralization
NCT07177053Phase 2Not yet recruiting
- Sponsor
- Dubai Health
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Nanoparticles, Device-based Delivery, Hydrogel Systems
01
Overview
Phase 2, randomised, open-label trial of calcium hydroxyapatite in Molar incisor hypomineralization (MIH) (2 arms), sponsored by Dubai Health. Primary endpoints: Enamel remineralization - Fluorescence Change (ΔF) at 12 months and Enamel remineralization - Lesion Area at 12 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
calcium hydroxyapatite
03
Conditions
Molar incisor hypomineralization (MIH)
Beyond the preview
Go deeper on NCT07177053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177053.